CRISPR Therapeutics reported strong second-quarter 2026 financial results, driven by significant growth in its blockbuster gene-edited therapy CASGEVY. The company generated $76 million in revenue for the quarter, representing a 78% increase from the previous quarter and a 151% year-over-year surge. This momentum was bolstered...
Metagenomi Therapeutics, Inc. (NASDAQ: MGX), an in vivo genome editing company headquartered in Emeryville, California, reported its first quarter 2026 financial results and key business milestones on May 11, 2026. The company maintains a substantial cash position with $140.2 million in cash, cash equivalents, and...
CRISPR Therapeutics (CRSP) stock has underperformed over the past year, trading 48% below the average Wall Street price target of $87.56 despite holding the only approved CRISPR-based gene therapy, CASGEVY. The company recently closed a $600 million convertible note offering, boosting its pro forma cash...
CRISPR Therapeutics reported financial results and a business update for the second quarter ended June 30, 2026. CEO Samarth Kulkarni highlighted strong execution across the portfolio, noting continued momentum for CASGEVY following FDA approval for children as young as two years old. The company also...
Crispr Therapeutics (CRSP) received FDA pediatric approval for Casgevy, a gene-editing therapy for sickle cell disease and beta-thalassemia. This regulatory milestone expands the company's addressable market and reinforces its leadership in CRISPR/Cas9 technology, despite previous challenges with complex treatment logistics and high costs associated with...
CRISPR Therapeutics (NASDAQ: CRSP) shares have recently declined, trading around $49.37 after dropping 5% in the past week and 8% year-to-date. Despite this short-term weakness, investment firm Piper Sandler has raised its price target to $110, implying over 120% upside potential from current levels. The...
The article compares CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals (VRTX), highlighting their distinct positions in the gene-editing space. CRISPR is characterized as a research-focused pioneer that recently secured its first product approval for CASGEVY, treating sickle cell disease and beta thalassemia. However, the company faces...
Shares of CRISPR Therapeutics (CRSP) have struggled significantly, dropping nearly 8% year-to-date and over 80% from their 2021 highs. The gene-editing company faces valuation challenges due to steep losses and a lack of recent major updates on its existing product pipeline. Compounding these issues is...
Shares of Intellia Therapeutics (NTLA) declined following news that Anthropic's AI model discovered a novel enzyme system associated with DNA repeats similar to CRISPR technology. However, the article argues this reaction is temporary and likely overblown, as the findings are early-stage discoveries years away from...
CRISPR Therapeutics is preparing for its initial public offering (IPO), having registered an S-1 form with the U.S. Securities and Exchange Commission. The company plans to price between 4 million and 5.4 million shares in a range of $15 to $17 per share, valuing the...
Amova Asset Management Americas Inc. reduced its stake in CRISPR Therapeutics AG by 5.3% during the first quarter, selling 104,236 shares and holding approximately 1.85 million shares valued at $88.19 million. The position represents about 1.2% of Amova's total holdings and ranks as its 26th...
Shares of CRISPR Therapeutics (CRSP) have struggled significantly, dropping nearly 8% year-to-date and over 80% from their 2021 highs. The gene-editing company faces valuation challenges due to steep losses and a lack of recent major updates on its existing product pipeline. Compounding these issues is...
Citizens Jmp reaffirmed its market outperform rating on CRISPR Therapeutics (CRSP) with a $80 price target, joining a chorus of recent analyst activity including Truist Financial's strong-buy upgrade and Piper Sandler raising its target to $110. While some analysts like Sanford C. Bernstein maintained hold...
CRISPR Therapeutics (NASDAQ:CRSP) received a mixed analyst outlook following a downgrade by Wall Street Zen to a 'sell' rating, which contrasts with recent upgrades from Piper Sandler and Truist Financial. The company maintains a consensus 'Moderate Buy' rating with an average price target of $67.78,...
CRISPR Therapeutics (NASDAQ:CRSP) saw its analyst rating upgraded to 'Hold' by Wall Street Zen, following a recent wave of mixed-to-positive sentiment from major institutions. Citigroup restated its rating to 'market outperform,' while Sanford C. Bernstein raised its price target to $56.00 and Evercore set an...
Simply Wall St analysis suggests CRISPR Therapeutics (CRSP) shares are trading at US$54.09, representing a significant discount to its estimated fair value of US$177.40 based on a discounted cash flow (DCF) model projecting future cash flows. The stock has demonstrated solid short-term momentum with a...
CRISPR Therapeutics (NASDAQ: CRSP) stock has experienced significant volatility as the market evaluates its transition from a clinical-stage biotech to a commercial entity. While the company achieved a major milestone in late 2023 with the regulatory approval of CASGEVY, the first CRISPR-based treatment for sickle...
CRISPR Therapeutics AG (CRSP) reported first-quarter earnings that missed both analyst estimates for loss and revenue. The company posted an adjusted loss of $1.28 per share, compared to the consensus expectation of a $1.14 loss and its own prior period's loss of $1.58. Revenue came...
CRISPR Therapeutics (CRSP) stock has experienced a short-term recovery, though long-term investors remain at a loss following a roughly 52.7% decline over the past five years. Current valuation metrics suggest the stock is priced toward an expensive reading rather than representing a clear bargain, trading...
